Covered recipient · General Payments record
MOHAMMAD R BOLOURI
Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2024 · Entire year
$25,153.09
51 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2024 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $14,200.00 | 10 |
| Compensation for serving as faculty or as a speaker for a medical education program | $5,850.00 | 5 |
| Travel and Lodging | $4,149.18 | 9 |
| Food and Beverage | $953.91 | 27 |
By paying entity
PY2024 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Lilly USA, LLC | $15,508.69 | 25 |
| Eisai Inc. | $8,210.30 | 16 |
| E.R. Squibb & Sons, L.L.C. | $1,302.85 | 3 |
| Otsuka America Pharmaceutical, Inc. | $60.04 | 3 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | $37.08 | 2 |
| Lundbeck LLC | $34.13 | 2 |
Page 2 of 2; records 51–51 of 51 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
MOHAMMAD R BOLOURI
NPI 1659322691 · CMS profile ID 29086
Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology
CHARLOTTE, NC
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 2; records 51–51 of 51 matching records. This page contains 1 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1659322691?year=2024&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- MOHAMMAD R BOLOURI, NPI 1659322691, CMS profile ID 29086. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–51 of 51 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1659322691?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- APA 7
- IndustryPayments. (2026). MOHAMMAD R BOLOURI, NPI 1659322691, CMS profile ID 29086. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–51 of 51 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1659322691?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- Bluebook
- MOHAMMAD R BOLOURI, NPI 1659322691, CMS profile ID 29086, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–51 of 51 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1659322691?year=2024&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2024
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30
51 matching records · $25,153.09 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–51 of 51.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Lundbeck LLC | $16.35 | 01/23/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1145898854 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $2,948,171.02 | 223 |
| PY2024 | Recipient | $42,149.90 | 1 |
| PY2024 | Principal investigator | $2,006,224.93 | 95 |
| PY2023 | Recipient | $150.00 | 1 |
| PY2023 | Principal investigator | $3,166,315.18 | 100 |
| PY2022 | Recipient | $250.00 | 1 |
| PY2022 | Principal investigator | $2,451,442.73 | 165 |
| PY2021 | Principal investigator | $2,459,911.12 | 123 |
| PY2020 | Recipient | $1,077.94 | 1 |
| PY2020 | Principal investigator | $1,535,993.16 | 168 |
| PY2019 | Principal investigator | $1,981,815.06 | 222 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
223 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Novo Nordisk AS | $700.00 | 12/22/2025 | Non-covered Recipient Entity ALZHEIMERS MEMORY CENTER FLOURISH RESEARCH | NN6535-4725 | No dispute reported | 06/30/2026 | 1213752234 |
| Principal investigator 1 | Novo Nordisk AS | $6,910.74 | 12/22/2025 | Non-covered Recipient Entity ALZHEIMERS MEMORY CENTER FLOURISH RESEARCH | NN6535-4725 | No dispute reported | 06/30/2026 | 1213806042 |
| Principal investigator 1 | Eisai Inc. | $6,013.80 | 12/15/2025 | Non-covered Recipient Entity AMC Research LLC | A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 1244557439 |
| Principal investigator 1 | Eisai Inc. | $5,500.00 | 12/01/2025 | Non-covered Recipient Entity AMC Research LLC | A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) | No dispute reported | 06/30/2026 | 1244557447 |
| Principal investigator 1 | Eisai Inc. | $11,550.00 | 12/01/2025 | Non-covered Recipient Entity AMC Research LLC | A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) | No dispute reported | 06/30/2026 | 1244557451 |
| Principal investigator 1 | Janssen Research & Development, LLC | $500.00 | 12/01/2025 | Non-covered Recipient Entity AMC RESEARCH | A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease | No dispute reported | 06/30/2026 | 1175418901 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $60.00 | 11/24/2025 | Non-covered Recipient Entity CLINICAL SITE PARTNERS LLC | A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE | No dispute reported | 06/30/2026 | 1192127237 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $60.00 | 11/24/2025 | Non-covered Recipient Entity CLINICAL SITE PARTNERS LLC | A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE | No dispute reported | 06/30/2026 | 1192135856 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $126.20 | 11/24/2025 | Non-covered Recipient Entity CLINICAL SITE PARTNERS LLC | A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE | No dispute reported | 06/30/2026 | 1192135991 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $301.86 | 11/24/2025 | Non-covered Recipient Entity CLINICAL SITE PARTNERS LLC | A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE | No dispute reported | 06/30/2026 | 1192142540 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $392.00 | 11/24/2025 | Non-covered Recipient Entity CLINICAL SITE PARTNERS LLC | A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE | No dispute reported | 06/30/2026 | 1192146342 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $179.20 | 11/24/2025 | Non-covered Recipient Entity CLINICAL SITE PARTNERS LLC | A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE | No dispute reported | 06/30/2026 | 1192184610 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $11,157.76 | 11/12/2025 | Non-covered Recipient Entity CLINICAL SITE PARTNERS LLC | A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE | No dispute reported | 06/30/2026 | 1192138273 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $58.80 | 11/06/2025 | Non-covered Recipient Entity CLINICAL SITE PARTNERS LLC | A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE | No dispute reported | 06/30/2026 | 1192127269 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $135.00 | 11/06/2025 | Non-covered Recipient Entity CLINICAL SITE PARTNERS LLC | A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE | No dispute reported | 06/30/2026 | 1192129399 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $270.00 | 11/06/2025 | Non-covered Recipient Entity CLINICAL SITE PARTNERS LLC | A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE | No dispute reported | 06/30/2026 | 1192135959 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $107.18 | 11/04/2025 | Non-covered Recipient Entity CLINICAL SITE PARTNERS LLC | A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE | No dispute reported | 06/30/2026 | 1192123165 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $179.20 | 11/04/2025 | Non-covered Recipient Entity CLINICAL SITE PARTNERS LLC | A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE | No dispute reported | 06/30/2026 | 1192129405 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $60.00 | 11/04/2025 | Non-covered Recipient Entity CLINICAL SITE PARTNERS LLC | A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE | No dispute reported | 06/30/2026 | 1192135893 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $60.00 | 11/04/2025 | Non-covered Recipient Entity CLINICAL SITE PARTNERS LLC | A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE | No dispute reported | 06/30/2026 | 1192136004 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $120.00 | 11/04/2025 | Non-covered Recipient Entity CLINICAL SITE PARTNERS LLC | A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE | No dispute reported | 06/30/2026 | 1192145202 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $179.20 | 11/04/2025 | Non-covered Recipient Entity CLINICAL SITE PARTNERS LLC | A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE | No dispute reported | 06/30/2026 | 1192145233 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $130.81 | 11/04/2025 | Non-covered Recipient Entity CLINICAL SITE PARTNERS LLC | A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE | No dispute reported | 06/30/2026 | 1192146346 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $120.00 | 11/04/2025 | Non-covered Recipient Entity CLINICAL SITE PARTNERS LLC | A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE | No dispute reported | 06/30/2026 | 1192180942 |
| Principal investigator 1 | Eisai Inc. | $15,200.00 | 11/01/2025 | Non-covered Recipient Entity AMC Research LLC | A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) | No dispute reported | 06/30/2026 | 1244557445 |
| Principal investigator 1 | Eisai Inc. | $11,340.00 | 11/01/2025 | Non-covered Recipient Entity AMC Research LLC | A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) | No dispute reported | 06/30/2026 | 1244557449 |
| Principal investigator 1 | Eisai Inc. | $3,870.00 | 11/01/2025 | Non-covered Recipient Entity AMC Research LLC | A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) | No dispute reported | 06/30/2026 | 1244557453 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $60.00 | 10/30/2025 | Non-covered Recipient Entity CLINICAL SITE PARTNERS LLC | A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE | No dispute reported | 06/30/2026 | 1192140726 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $405.00 | 10/30/2025 | Non-covered Recipient Entity CLINICAL SITE PARTNERS LLC | A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE | No dispute reported | 06/30/2026 | 1192179635 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $810.00 | 10/30/2025 | Non-covered Recipient Entity CLINICAL SITE PARTNERS LLC | A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE | No dispute reported | 06/30/2026 | 1192184639 |
| Principal investigator 1 | Eisai Inc. | $250.00 | 10/21/2025 | Non-covered Recipient Entity AMC Research LLC | A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 1244557435 |
| Principal investigator 1 | Eisai Inc. | $22,770.90 | 10/20/2025 | Non-covered Recipient Entity AMC Research LLC | A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 1244557437 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $34,873.20 | 10/20/2025 | Non-covered Recipient Entity CLINICAL SITE PARTNERS LLC | A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE | No dispute reported | 06/30/2026 | 1192146363 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $57.12 | 10/20/2025 | Non-covered Recipient Entity CLINICAL SITE PARTNERS LLC | A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE | No dispute reported | 06/30/2026 | 1192180962 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $60.00 | 10/17/2025 | Non-covered Recipient Entity CLINICAL SITE PARTNERS LLC | A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE | No dispute reported | 06/30/2026 | 1192123173 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $57.21 | 10/17/2025 | Non-covered Recipient Entity CLINICAL SITE PARTNERS LLC | A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE | No dispute reported | 06/30/2026 | 1192123192 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $120.00 | 10/17/2025 | Non-covered Recipient Entity CLINICAL SITE PARTNERS LLC | A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE | No dispute reported | 06/30/2026 | 1192127229 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $6,000.00 | 10/17/2025 | Non-covered Recipient Entity CLINICAL SITE PARTNERS LLC | A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE | No dispute reported | 06/30/2026 | 1192127284 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $60.00 | 10/17/2025 | Non-covered Recipient Entity CLINICAL SITE PARTNERS LLC | A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE | No dispute reported | 06/30/2026 | 1192135951 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $62.37 | 10/17/2025 | Non-covered Recipient Entity CLINICAL SITE PARTNERS LLC | A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE | No dispute reported | 06/30/2026 | 1192135997 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $56.79 | 10/17/2025 | Non-covered Recipient Entity CLINICAL SITE PARTNERS LLC | A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE | No dispute reported | 06/30/2026 | 1192140714 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $358.40 | 10/17/2025 | Non-covered Recipient Entity CLINICAL SITE PARTNERS LLC | A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE | No dispute reported | 06/30/2026 | 1192140720 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $57.12 | 10/17/2025 | Non-covered Recipient Entity CLINICAL SITE PARTNERS LLC | A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE | No dispute reported | 06/30/2026 | 1192140731 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $179.20 | 10/17/2025 | Non-covered Recipient Entity CLINICAL SITE PARTNERS LLC | A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE | No dispute reported | 06/30/2026 | 1192140735 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $610.40 | 10/17/2025 | Non-covered Recipient Entity CLINICAL SITE PARTNERS LLC | A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE | No dispute reported | 06/30/2026 | 1192142502 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $311.50 | 10/17/2025 | Non-covered Recipient Entity CLINICAL SITE PARTNERS LLC | A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE | No dispute reported | 06/30/2026 | 1192142528 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $179.20 | 10/17/2025 | Non-covered Recipient Entity CLINICAL SITE PARTNERS LLC | A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE | No dispute reported | 06/30/2026 | 1192148488 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $60.00 | 10/17/2025 | Non-covered Recipient Entity CLINICAL SITE PARTNERS LLC | A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE | No dispute reported | 06/30/2026 | 1192180958 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $179.20 | 10/17/2025 | Non-covered Recipient Entity CLINICAL SITE PARTNERS LLC | A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE | No dispute reported | 06/30/2026 | 1192184621 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,080.00 | 10/16/2025 | Non-covered Recipient Entity CLINICAL SITE PARTNERS LLC | A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE | No dispute reported | 06/30/2026 | 1192127261 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $540.00 | 10/16/2025 | Non-covered Recipient Entity CLINICAL SITE PARTNERS LLC | A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE | No dispute reported | 06/30/2026 | 1192135864 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $58.80 | 10/16/2025 | Non-covered Recipient Entity CLINICAL SITE PARTNERS LLC | A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE | No dispute reported | 06/30/2026 | 1192135979 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $607.50 | 10/16/2025 | Non-covered Recipient Entity CLINICAL SITE PARTNERS LLC | A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE | No dispute reported | 06/30/2026 | 1192138267 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $270.00 | 10/16/2025 | Non-covered Recipient Entity CLINICAL SITE PARTNERS LLC | A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE | No dispute reported | 06/30/2026 | 1192146355 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $540.00 | 10/16/2025 | Non-covered Recipient Entity CLINICAL SITE PARTNERS LLC | A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE | No dispute reported | 06/30/2026 | 1192148511 |
| Principal investigator 1 | Eisai Inc. | $7,600.00 | 10/01/2025 | Non-covered Recipient Entity AMC Research LLC | A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) | No dispute reported | 06/30/2026 | 1244557441 |
| Principal investigator 1 | Eisai Inc. | $7,750.00 | 10/01/2025 | Non-covered Recipient Entity AMC Research LLC | A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) | No dispute reported | 06/30/2026 | 1244557443 |
| Principal investigator 1 | Eisai Inc. | $16,375.00 | 10/01/2025 | Non-covered Recipient Entity AMC Research LLC | A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) | No dispute reported | 06/30/2026 | 1244557455 |
| Principal investigator 1 | Novo Nordisk AS | $779.76 | 09/19/2025 | Non-covered Recipient Entity ALZHEIMERS MEMORY CENTER FLOURISH RESEARCH | NN6535-4725 | No dispute reported | 06/30/2026 | 1214102707 |
| Principal investigator 1 | Eisai Inc. | $13,199.40 | 09/15/2025 | Non-covered Recipient Entity AMC Research LLC | A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 1244557433 |
| Principal investigator 1 | Janssen Research & Development, LLC | $7,704.00 | 09/15/2025 | Non-covered Recipient Entity AMC RESEARCH | A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease | No dispute reported | 06/30/2026 | 1175418881 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,626.00 | 09/15/2025 | Non-covered Recipient Entity AMC RESEARCH | A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease | No dispute reported | 06/30/2026 | 1175418950 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $16,935.75 | 09/12/2025 | Non-covered Recipient Entity CLINICAL SITE PARTNERS LLC | A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE | No dispute reported | 06/30/2026 | 1192129412 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $270.00 | 09/12/2025 | Non-covered Recipient Entity CLINICAL SITE PARTNERS LLC | A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE | No dispute reported | 06/30/2026 | 1192145210 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $135.00 | 09/12/2025 | Non-covered Recipient Entity CLINICAL SITE PARTNERS LLC | A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE | No dispute reported | 06/30/2026 | 1192145225 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $270.00 | 09/05/2025 | Non-covered Recipient Entity CLINICAL SITE PARTNERS LLC | A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE | No dispute reported | 06/30/2026 | 1192135897 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $135.00 | 09/05/2025 | Non-covered Recipient Entity CLINICAL SITE PARTNERS LLC | A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE | No dispute reported | 06/30/2026 | 1192145229 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $120.00 | 09/05/2025 | Non-covered Recipient Entity CLINICAL SITE PARTNERS LLC | A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE | No dispute reported | 06/30/2026 | 1192148481 |
| Principal investigator 1 | Biogen, Inc. | $14,730.03 | 09/03/2025 | Non-covered Recipient Entity ALZHEIMERS MEMORY CENTER | A Phase 3b/4 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Verify the Clinical Benefit of Aducanumab (BIIB037) in Participants With Alzheimer's Disease | No dispute reported | 06/30/2026 | 1236946856 |
| Principal investigator 1 | Eisai Inc. | $7,120.00 | 09/01/2025 | Non-covered Recipient Entity AMC Research LLC | A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) | No dispute reported | 06/30/2026 | 1244557465 |
| Principal investigator 1 | Eisai Inc. | $3,870.00 | 09/01/2025 | Non-covered Recipient Entity AMC Research LLC | A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) | No dispute reported | 06/30/2026 | 1244557487 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $405.00 | 09/01/2025 | Non-covered Recipient Entity CLINICAL SITE PARTNERS LLC | A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE | No dispute reported | 06/30/2026 | 1192127255 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $120.00 | 09/01/2025 | Non-covered Recipient Entity CLINICAL SITE PARTNERS LLC | A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE | No dispute reported | 06/30/2026 | 1192129370 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $810.00 | 09/01/2025 | Non-covered Recipient Entity CLINICAL SITE PARTNERS LLC | A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE | No dispute reported | 06/30/2026 | 1192179631 |
| Principal investigator 1 | ABBVIE INC. | $2,600.00 | 08/27/2025 | Non-covered Recipient Entity AMC RESEARCH LLC | A Study to Assess Safety of ABBV-916 and How Intravenous ABBV-916 Moves Through Body and Affects Brain Amyloid Plaque Clearance in Adult Participants (Aged 50-90 Years) With Early Alzheimer Disease | No dispute reported | 06/30/2026 | 1202505969 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $57.12 | 08/26/2025 | Non-covered Recipient Entity CLINICAL SITE PARTNERS LLC | A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE | No dispute reported | 06/30/2026 | 1192123205 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $103.73 | 08/26/2025 | Non-covered Recipient Entity CLINICAL SITE PARTNERS LLC | A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE | No dispute reported | 06/30/2026 | 1192184614 |
| Principal investigator 1 | Novo Nordisk AS | $6,964.74 | 08/22/2025 | Non-covered Recipient Entity ALZHEIMERS MEMORY CENTER FLOURISH RESEARCH | NN6535-4725 | No dispute reported | 06/30/2026 | 1214103579 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $12,973.50 | 08/13/2025 | Non-covered Recipient Entity CLINICAL SITE PARTNERS LLC | A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE | No dispute reported | 06/30/2026 | 1192142515 |
| Principal investigator 1 | Eisai Inc. | $10,642.50 | 08/11/2025 | Non-covered Recipient Entity AMC Research LLC | A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 1244557431 |
| Principal investigator 1 | Janssen Research & Development, LLC | $500.00 | 08/11/2025 | Non-covered Recipient Entity AMC RESEARCH | A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease | No dispute reported | 06/30/2026 | 1175418985 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,720.00 | 08/08/2025 | Non-covered Recipient Entity AMC RESEARCH | A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease | No dispute reported | 06/30/2026 | 1175418876 |
| Principal investigator 1 | Janssen Research & Development, LLC | $38,790.00 | 08/08/2025 | Non-covered Recipient Entity AMC RESEARCH | A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease | No dispute reported | 06/30/2026 | 1175418887 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,400.00 | 08/08/2025 | Non-covered Recipient Entity AMC RESEARCH | A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease | No dispute reported | 06/30/2026 | 1175418913 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $229.92 | 08/06/2025 | Non-covered Recipient Entity CLINICAL SITE PARTNERS LLC | A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE | No dispute reported | 06/30/2026 | 1192123187 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $103.03 | 08/06/2025 | Non-covered Recipient Entity CLINICAL SITE PARTNERS LLC | A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE | No dispute reported | 06/30/2026 | 1192135877 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $86.44 | 08/06/2025 | Non-covered Recipient Entity CLINICAL SITE PARTNERS LLC | A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE | No dispute reported | 06/30/2026 | 1192148493 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $540.00 | 08/05/2025 | Non-covered Recipient Entity CLINICAL SITE PARTNERS LLC | A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE | No dispute reported | 06/30/2026 | 1192140742 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,080.00 | 08/05/2025 | Non-covered Recipient Entity CLINICAL SITE PARTNERS LLC | A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE | No dispute reported | 06/30/2026 | 1192142508 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $405.00 | 07/29/2025 | Non-covered Recipient Entity CLINICAL SITE PARTNERS LLC | A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE | No dispute reported | 06/30/2026 | 1192127243 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $202.50 | 07/29/2025 | Non-covered Recipient Entity CLINICAL SITE PARTNERS LLC | A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE | No dispute reported | 06/30/2026 | 1192135871 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $2,786.09 | 07/28/2025 | Non-covered Recipient Entity Alzheimers Memory Center Flourish Research | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for the Treatment of Cognitive Impairment Associated with Mild-to-Moderate Alzheimers Disease (MINDSET 1) | No dispute reported | 06/30/2026 | 1235999059 |
| Principal investigator 1 | Janssen Research & Development, LLC | $19,916.00 | 07/25/2025 | Non-covered Recipient Entity AMC RESEARCH | A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease | No dispute reported | 06/30/2026 | 1175419011 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,680.00 | 07/24/2025 | Non-covered Recipient Entity AMC RESEARCH | A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease | No dispute reported | 06/30/2026 | 1175418830 |
| Principal investigator 1 | Janssen Research & Development, LLC | $7,119.00 | 07/24/2025 | Non-covered Recipient Entity AMC RESEARCH | A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease | No dispute reported | 06/30/2026 | 1175418841 |
| Principal investigator 1 | Janssen Research & Development, LLC | $9,404.00 | 07/24/2025 | Non-covered Recipient Entity AMC RESEARCH | A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease | No dispute reported | 06/30/2026 | 1175418853 |
| Principal investigator 1 | Janssen Research & Development, LLC | $250.00 | 07/24/2025 | Non-covered Recipient Entity AMC RESEARCH | A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease | No dispute reported | 06/30/2026 | 1175418870 |
| Principal investigator 1 | Janssen Research & Development, LLC | $520.00 | 07/24/2025 | Non-covered Recipient Entity AMC RESEARCH | A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease | No dispute reported | 06/30/2026 | 1175418939 |
| Principal investigator 1 | Janssen Research & Development, LLC | $520.00 | 07/24/2025 | Non-covered Recipient Entity AMC RESEARCH | A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease | No dispute reported | 06/30/2026 | 1175418944 |
| Principal investigator 1 | Janssen Research & Development, LLC | $15,744.00 | 07/24/2025 | Non-covered Recipient Entity AMC RESEARCH | A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease | No dispute reported | 06/30/2026 | 1175419003 |
| Principal investigator 1 | Eisai Inc. | $8,554.50 | 07/21/2025 | Non-covered Recipient Entity AMC Research LLC | A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 1244557429 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $21,595.95 | 07/21/2025 | Non-covered Recipient Entity CLINICAL SITE PARTNERS LLC | A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE | No dispute reported | 06/30/2026 | 1192145206 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $118,027.19 | 07/14/2025 | Non-covered Recipient Entity Alzheimers Memory Center Flourish Research | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for the Treatment of Cognitive Impairment Associated with Mild-to-Moderate Alzheimers Disease (MINDSET 1) | No dispute reported | 06/30/2026 | 1235999063 |
| Principal investigator 1 | Eisai Inc. | $18,110.70 | 07/07/2025 | Non-covered Recipient Entity AMC Research LLC | A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 1244557427 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,759.00 | 07/07/2025 | Non-covered Recipient Entity AMC RESEARCH | A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease | No dispute reported | 06/30/2026 | 1175418926 |
| Principal investigator 1 | Eisai Inc. | $7,685.00 | 07/01/2025 | Non-covered Recipient Entity AMC Research LLC | A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) | No dispute reported | 06/30/2026 | 1244557457 |
| Principal investigator 1 | Eisai Inc. | $14,315.00 | 07/01/2025 | Non-covered Recipient Entity AMC Research LLC | A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) | No dispute reported | 06/30/2026 | 1244557467 |
| Principal investigator 1 | Eisai Inc. | $14,280.00 | 07/01/2025 | Non-covered Recipient Entity AMC Research LLC | A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) | No dispute reported | 06/30/2026 | 1244557475 |
| Principal investigator 1 | Eisai Inc. | $5,760.00 | 07/01/2025 | Non-covered Recipient Entity AMC Research LLC | A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) | No dispute reported | 06/30/2026 | 1244557483 |
| Principal investigator 1 | Eisai Inc. | $3,800.00 | 07/01/2025 | Non-covered Recipient Entity AMC Research LLC | A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) | No dispute reported | 06/30/2026 | 1244557485 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $378.13 | 06/24/2025 | Non-covered Recipient Entity Alzheimers Memory Center Flourish Research | Phase III Safety and Efficacy of KarXT in Psychosis Associated with AD (ADEPT 4): 2 of 2 Acute Studies | No dispute reported | 06/30/2026 | 1235999067 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $14,800.06 | 06/23/2025 | Non-covered Recipient Entity CLINICAL SITE PARTNERS LLC | A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE | No dispute reported | 06/30/2026 | 1192145198 |
| Principal investigator 1 | Janssen Research & Development, LLC | $18,818.00 | 06/23/2025 | Non-covered Recipient Entity AMC RESEARCH | A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease | No dispute reported | 06/30/2026 | 1175418847 |
| Principal investigator 1 | Janssen Research & Development, LLC | $500.00 | 06/23/2025 | Non-covered Recipient Entity AMC RESEARCH | A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease | No dispute reported | 06/30/2026 | 1175419064 |
| Principal investigator 1 | Novo Nordisk AS | $2,329.02 | 06/23/2025 | Non-covered Recipient Entity ALZHEIMERS MEMORY CENTER FLOURISH RESEARCH | NN6535-4725 | No dispute reported | 06/30/2026 | 1214102391 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $18,381.00 | 06/18/2025 | Non-covered Recipient Entity Alzheimers Memory Center Flourish Research | Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects with Psychosis Associated with Alzheimers Disease Dementia | No dispute reported | 06/30/2026 | 1235999057 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $270.00 | 06/18/2025 | Non-covered Recipient Entity CLINICAL SITE PARTNERS LLC | A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE | No dispute reported | 06/30/2026 | 1192145220 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $135.00 | 06/18/2025 | Non-covered Recipient Entity CLINICAL SITE PARTNERS LLC | A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE | No dispute reported | 06/30/2026 | 1192149353 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,080.00 | 06/17/2025 | Non-covered Recipient Entity CLINICAL SITE PARTNERS LLC | A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE | No dispute reported | 06/30/2026 | 1192135886 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $540.00 | 06/17/2025 | Non-covered Recipient Entity CLINICAL SITE PARTNERS LLC | A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE | No dispute reported | 06/30/2026 | 1192135967 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $40.50 | 06/17/2025 | Non-covered Recipient Entity CLINICAL SITE PARTNERS LLC | A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE | No dispute reported | 06/30/2026 | 1192138224 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $270.00 | 06/17/2025 | Non-covered Recipient Entity CLINICAL SITE PARTNERS LLC | A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE | No dispute reported | 06/30/2026 | 1192148497 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $540.00 | 06/17/2025 | Non-covered Recipient Entity CLINICAL SITE PARTNERS LLC | A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE | No dispute reported | 06/30/2026 | 1192149348 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $135.00 | 06/17/2025 | Non-covered Recipient Entity CLINICAL SITE PARTNERS LLC | A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE | No dispute reported | 06/30/2026 | 1192179639 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $270.00 | 06/17/2025 | Non-covered Recipient Entity CLINICAL SITE PARTNERS LLC | A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE | No dispute reported | 06/30/2026 | 1192180944 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $540.00 | 06/17/2025 | Non-covered Recipient Entity CLINICAL SITE PARTNERS LLC | A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE | No dispute reported | 06/30/2026 | 1192184625 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $5,805.00 | 06/06/2025 | Non-covered Recipient Entity CLINICAL SITE PARTNERS LLC | A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE | No dispute reported | 06/30/2026 | 1192129378 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,080.00 | 06/06/2025 | Non-covered Recipient Entity CLINICAL SITE PARTNERS LLC | A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE | No dispute reported | 06/30/2026 | 1192184634 |
| Principal investigator 1 | Eisai Inc. | $7,675.00 | 06/01/2025 | Non-covered Recipient Entity AMC Research LLC | A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) | No dispute reported | 06/30/2026 | 1244557469 |
| Principal investigator 1 | Eisai Inc. | $19,855.00 | 06/01/2025 | Non-covered Recipient Entity AMC Research LLC | A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) | No dispute reported | 06/30/2026 | 1244557473 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $675.00 | 05/30/2025 | Non-covered Recipient Entity CLINICAL SITE PARTNERS LLC | A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE | No dispute reported | 06/30/2026 | 1192129392 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $270.00 | 05/30/2025 | Non-covered Recipient Entity CLINICAL SITE PARTNERS LLC | A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE | No dispute reported | 06/30/2026 | 1192135986 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $135.00 | 05/30/2025 | Non-covered Recipient Entity CLINICAL SITE PARTNERS LLC | A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE | No dispute reported | 06/30/2026 | 1192142495 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $40.50 | 05/30/2025 | Non-covered Recipient Entity CLINICAL SITE PARTNERS LLC | A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE | No dispute reported | 06/30/2026 | 1192142522 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $135.00 | 05/30/2025 | Non-covered Recipient Entity CLINICAL SITE PARTNERS LLC | A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE | No dispute reported | 06/30/2026 | 1192146351 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,350.00 | 05/30/2025 | Non-covered Recipient Entity CLINICAL SITE PARTNERS LLC | A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE | No dispute reported | 06/30/2026 | 1192148484 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $60.00 | 05/30/2025 | Non-covered Recipient Entity CLINICAL SITE PARTNERS LLC | A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE | No dispute reported | 06/30/2026 | 1192179659 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $270.00 | 05/30/2025 | Non-covered Recipient Entity CLINICAL SITE PARTNERS LLC | A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE | No dispute reported | 06/30/2026 | 1192184617 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $540.00 | 05/26/2025 | Non-covered Recipient Entity CLINICAL SITE PARTNERS LLC | A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE | No dispute reported | 06/30/2026 | 1192148501 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $270.00 | 05/26/2025 | Non-covered Recipient Entity CLINICAL SITE PARTNERS LLC | A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE | No dispute reported | 06/30/2026 | 1192149357 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $405.00 | 05/26/2025 | Non-covered Recipient Entity CLINICAL SITE PARTNERS LLC | A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE | No dispute reported | 06/30/2026 | 1192176833 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $202.50 | 05/26/2025 | Non-covered Recipient Entity CLINICAL SITE PARTNERS LLC | A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE | No dispute reported | 06/30/2026 | 1192179647 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $810.00 | 05/26/2025 | Non-covered Recipient Entity CLINICAL SITE PARTNERS LLC | A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE | No dispute reported | 06/30/2026 | 1192179655 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $405.00 | 05/26/2025 | Non-covered Recipient Entity CLINICAL SITE PARTNERS LLC | A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE | No dispute reported | 06/30/2026 | 1192180934 |
| Principal investigator 1 | Novo Nordisk AS | $779.76 | 05/21/2025 | Non-covered Recipient Entity ALZHEIMERS MEMORY CENTER FLOURISH RESEARCH | NN6535-4725 | No dispute reported | 06/30/2026 | 1214102505 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,250.00 | 05/19/2025 | Non-covered Recipient Entity AMC RESEARCH | A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease | No dispute reported | 06/30/2026 | 1175418956 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $12,638.70 | 05/13/2025 | Non-covered Recipient Entity CLINICAL SITE PARTNERS LLC | A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE | No dispute reported | 06/30/2026 | 1192142534 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,080.00 | 05/09/2025 | Non-covered Recipient Entity AMC RESEARCH | A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease | No dispute reported | 06/30/2026 | 1175419022 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,175.00 | 05/09/2025 | Non-covered Recipient Entity AMC RESEARCH | A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease | No dispute reported | 06/30/2026 | 1175419040 |
| Principal investigator 1 | Janssen Research & Development, LLC | $16,065.00 | 05/05/2025 | Non-covered Recipient Entity AMC RESEARCH | A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease | No dispute reported | 06/30/2026 | 1175418991 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $135.00 | 04/28/2025 | Non-covered Recipient Entity CLINICAL SITE PARTNERS LLC | A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE | No dispute reported | 06/30/2026 | 1192123199 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $810.00 | 04/28/2025 | Non-covered Recipient Entity CLINICAL SITE PARTNERS LLC | A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE | No dispute reported | 06/30/2026 | 1192127275 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $797.85 | 04/28/2025 | Non-covered Recipient Entity CLINICAL SITE PARTNERS LLC | A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE | No dispute reported | 06/30/2026 | 1192135903 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $54.00 | 04/28/2025 | Non-covered Recipient Entity CLINICAL SITE PARTNERS LLC | A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE | No dispute reported | 06/30/2026 | 1192138237 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $405.00 | 04/28/2025 | Non-covered Recipient Entity CLINICAL SITE PARTNERS LLC | A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE | No dispute reported | 06/30/2026 | 1192148505 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,250.00 | 04/21/2025 | Non-covered Recipient Entity AMC RESEARCH | A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease | No dispute reported | 06/30/2026 | 1175418864 |
| Principal investigator 1 | Janssen Research & Development, LLC | $798.00 | 04/21/2025 | Non-covered Recipient Entity AMC RESEARCH | A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease | No dispute reported | 06/30/2026 | 1175418893 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,508.00 | 04/21/2025 | Non-covered Recipient Entity AMC RESEARCH | A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease | No dispute reported | 06/30/2026 | 1175418995 |
| Principal investigator 1 | Janssen Research & Development, LLC | $684.00 | 04/21/2025 | Non-covered Recipient Entity AMC RESEARCH | A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease | No dispute reported | 06/30/2026 | 1175419016 |
| Principal investigator 1 | Janssen Research & Development, LLC | $13,490.00 | 04/21/2025 | Non-covered Recipient Entity AMC RESEARCH | A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease | No dispute reported | 06/30/2026 | 1175419029 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $30,015.23 | 04/09/2025 | Non-covered Recipient Entity CLINICAL SITE PARTNERS LLC | A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE | No dispute reported | 06/30/2026 | 1192146359 |
| Principal investigator 1 | Genentech, Inc. | $794.14 | 04/08/2025 | Non-covered Recipient Entity AMC RESEARCH LLC MOHAMMAD REZA BOLOURI MD | PoM study of Brain Shuttle Gantenerumab in early AD | No dispute reported | 06/30/2026 | 1211572081 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $540.00 | 04/03/2025 | Non-covered Recipient Entity CLINICAL SITE PARTNERS LLC | A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE | No dispute reported | 06/30/2026 | 1192129364 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $270.00 | 04/03/2025 | Non-covered Recipient Entity CLINICAL SITE PARTNERS LLC | A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE | No dispute reported | 06/30/2026 | 1192135974 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $202.50 | 04/03/2025 | Non-covered Recipient Entity CLINICAL SITE PARTNERS LLC | A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE | No dispute reported | 06/30/2026 | 1192138251 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $270.00 | 04/03/2025 | Non-covered Recipient Entity CLINICAL SITE PARTNERS LLC | A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE | No dispute reported | 06/30/2026 | 1192138260 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $540.00 | 04/03/2025 | Non-covered Recipient Entity CLINICAL SITE PARTNERS LLC | A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE | No dispute reported | 06/30/2026 | 1192145215 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $4,995.00 | 04/03/2025 | Non-covered Recipient Entity CLINICAL SITE PARTNERS LLC | A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE | No dispute reported | 06/30/2026 | 1192179643 |
| Principal investigator 1 | Eisai Inc. | $215.00 | 04/01/2025 | Non-covered Recipient Entity AMC Research LLC | A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) | No dispute reported | 06/30/2026 | 1244557477 |
| Principal investigator 1 | Eisai Inc. | $430.00 | 04/01/2025 | Non-covered Recipient Entity AMC Research LLC | A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) | No dispute reported | 06/30/2026 | 1244557479 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,500.00 | 04/01/2025 | Non-covered Recipient Entity CLINICAL SITE PARTNERS LLC | A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE | No dispute reported | 06/30/2026 | 1192149341 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $202.50 | 04/01/2025 | Non-covered Recipient Entity CLINICAL SITE PARTNERS LLC | A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE | No dispute reported | 06/30/2026 | 1192184630 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,414.00 | 03/31/2025 | Non-covered Recipient Entity AMC RESEARCH | A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease | No dispute reported | 06/30/2026 | 1175418836 |
| Principal investigator 1 | Janssen Research & Development, LLC | $250.00 | 03/31/2025 | Non-covered Recipient Entity AMC RESEARCH | A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease | No dispute reported | 06/30/2026 | 1175418919 |
| Principal investigator 1 | Janssen Research & Development, LLC | $9,900.00 | 03/31/2025 | Non-covered Recipient Entity AMC RESEARCH | A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease | No dispute reported | 06/30/2026 | 1175418932 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,660.00 | 03/31/2025 | Non-covered Recipient Entity AMC RESEARCH | A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease | No dispute reported | 06/30/2026 | 1175418962 |
| Principal investigator 1 | Janssen Research & Development, LLC | $224,910.00 | 03/31/2025 | Non-covered Recipient Entity AMC RESEARCH | A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease | No dispute reported | 06/30/2026 | 1175418973 |
| Principal investigator 1 | Janssen Research & Development, LLC | $500.00 | 03/31/2025 | Non-covered Recipient Entity AMC RESEARCH | A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease | No dispute reported | 06/30/2026 | 1175419054 |
| Principal investigator 1 | Janssen Research & Development, LLC | $25,860.00 | 03/31/2025 | Non-covered Recipient Entity AMC RESEARCH | A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease | No dispute reported | 06/30/2026 | 1175419070 |
| Principal investigator 1 | Novo Nordisk AS | $981.18 | 03/28/2025 | Non-covered Recipient Entity ALZHEIMERS MEMORY CENTER FLOURISH RESEARCH | NN6535-4725 | No dispute reported | 06/30/2026 | 1214103629 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $21,089.71 | 03/21/2025 | Non-covered Recipient Entity CLINICAL SITE PARTNERS LLC | A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE | No dispute reported | 06/30/2026 | 1192140749 |
| Principal investigator 1 | Eisai Inc. | $54,127.80 | 03/18/2025 | Non-covered Recipient Entity AMC Research LLC | A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 1244557425 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $202.50 | 03/06/2025 | Non-covered Recipient Entity CLINICAL SITE PARTNERS LLC | A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE | No dispute reported | 06/30/2026 | 1192129385 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $270.00 | 03/06/2025 | Non-covered Recipient Entity CLINICAL SITE PARTNERS LLC | A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE | No dispute reported | 06/30/2026 | 1192135848 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $405.00 | 03/06/2025 | Non-covered Recipient Entity CLINICAL SITE PARTNERS LLC | A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE | No dispute reported | 06/30/2026 | 1192138245 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $4,995.00 | 03/06/2025 | Non-covered Recipient Entity CLINICAL SITE PARTNERS LLC | A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE | No dispute reported | 06/30/2026 | 1192140708 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $405.00 | 03/06/2025 | Non-covered Recipient Entity CLINICAL SITE PARTNERS LLC | A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE | No dispute reported | 06/30/2026 | 1192146371 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $40.50 | 03/06/2025 | Non-covered Recipient Entity CLINICAL SITE PARTNERS LLC | A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE | No dispute reported | 06/30/2026 | 1192149336 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $5,805.00 | 03/06/2025 | Non-covered Recipient Entity CLINICAL SITE PARTNERS LLC | A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE | No dispute reported | 06/30/2026 | 1192149345 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $202.50 | 03/06/2025 | Non-covered Recipient Entity CLINICAL SITE PARTNERS LLC | A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE | No dispute reported | 06/30/2026 | 1192180949 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $135.00 | 03/06/2025 | Non-covered Recipient Entity CLINICAL SITE PARTNERS LLC | A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE | No dispute reported | 06/30/2026 | 1192180953 |
| Principal investigator 1 | Eisai Inc. | $5,290.00 | 03/01/2025 | Non-covered Recipient Entity AMC Research LLC | A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) | No dispute reported | 06/30/2026 | 1244557461 |
| Principal investigator 1 | Eisai Inc. | $7,745.00 | 03/01/2025 | Non-covered Recipient Entity AMC Research LLC | A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) | No dispute reported | 06/30/2026 | 1244557471 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $405.00 | 02/25/2025 | Non-covered Recipient Entity CLINICAL SITE PARTNERS LLC | A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE | No dispute reported | 06/30/2026 | 1192123180 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $150.00 | 02/25/2025 | Non-covered Recipient Entity CLINICAL SITE PARTNERS LLC | A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE | No dispute reported | 06/30/2026 | 1192123211 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $5,805.00 | 02/25/2025 | Non-covered Recipient Entity CLINICAL SITE PARTNERS LLC | A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE | No dispute reported | 06/30/2026 | 1192146368 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $60.00 | 02/25/2025 | Non-covered Recipient Entity CLINICAL SITE PARTNERS LLC | A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE | No dispute reported | 06/30/2026 | 1192149361 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,080.00 | 02/25/2025 | Non-covered Recipient Entity CLINICAL SITE PARTNERS LLC | A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE | No dispute reported | 06/30/2026 | 1192149365 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $60.00 | 02/25/2025 | Non-covered Recipient Entity CLINICAL SITE PARTNERS LLC | A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE | No dispute reported | 06/30/2026 | 1192179651 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $540.00 | 02/25/2025 | Non-covered Recipient Entity CLINICAL SITE PARTNERS LLC | A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE | No dispute reported | 06/30/2026 | 1192180938 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $27,837.68 | 02/24/2025 | Non-covered Recipient Entity CLINICAL SITE PARTNERS LLC | A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE | No dispute reported | 06/30/2026 | 1192138230 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $458,902.87 | 02/11/2025 | Non-covered Recipient Entity Alzheimers Memory Center Flourish Research | A Randomized, Double-blind, Placebo-controlled, Global Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986446, an Anti-MTBR Tau Monoclonal Antibody, in Participants with Early Alzheimers Disease (TargetTau-1) | No dispute reported | 06/30/2026 | 1235999061 |
| Principal investigator 1 | Eli Lilly and Company | $79,916.00 | 02/10/2025 | Non-covered Recipient Entity ALZHEIMER'S MEMORY CENTER | ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | No dispute reported | 06/30/2026 | 1187876553 |
| Principal investigator 1 | Janssen Research & Development, LLC | $82,620.00 | 02/07/2025 | Non-covered Recipient Entity AMC RESEARCH | A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease | No dispute reported | 06/30/2026 | 1175418858 |
| Principal investigator 1 | Janssen Research & Development, LLC | $13,770.00 | 02/07/2025 | Non-covered Recipient Entity AMC RESEARCH | A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease | No dispute reported | 06/30/2026 | 1175418907 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,204.00 | 02/07/2025 | Non-covered Recipient Entity AMC RESEARCH | A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease | No dispute reported | 06/30/2026 | 1175418969 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,964.00 | 02/07/2025 | Non-covered Recipient Entity AMC RESEARCH | A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease | No dispute reported | 06/30/2026 | 1175418979 |
| Principal investigator 1 | Janssen Research & Development, LLC | $684.00 | 02/07/2025 | Non-covered Recipient Entity AMC RESEARCH | A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease | No dispute reported | 06/30/2026 | 1175419035 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,596.00 | 02/07/2025 | Non-covered Recipient Entity AMC RESEARCH | A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease | No dispute reported | 06/30/2026 | 1175419047 |
| Principal investigator 1 | Janssen Research & Development, LLC | $114,750.00 | 02/07/2025 | Non-covered Recipient Entity AMC RESEARCH | A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease | No dispute reported | 06/30/2026 | 1175419060 |
| Principal investigator 1 | Eisai Inc. | $6,000.00 | 02/01/2025 | Non-covered Recipient Entity AMC Research LLC | A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) | No dispute reported | 06/30/2026 | 1244557481 |
| Principal investigator 1 | Eli Lilly and Company | $7,693.83 | 01/31/2025 | Non-covered Recipient Entity ALZHEIMERS MEMORY CENTER | A RANDOMIZED, DOUBLE-BLINDED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MEVIDALEN IN PATIENTS WITH ALZHEIMER'S DISEASE | No dispute reported | 06/30/2026 | 1187876551 |
| Principal investigator 1 | Novo Nordisk AS | $5,383.80 | 01/31/2025 | Non-covered Recipient Entity ALZHEIMERS MEMORY CENTER FLOURISH RESEARCH | NN6535-4725 | No dispute reported | 06/30/2026 | 1214103455 |
| Principal investigator 1 | Biogen, Inc. | $21,799.00 | 01/28/2025 | Non-covered Recipient Entity ALZHEIMERS MEMORY CENTER | Phase 3b Open-Label, Multicenter, Safety Study of BIIB037 (aducanumab) in Subjects with Alzheimers disease Who Had Previously Participated in the Aducanumab Studies221AD103, 221AD301, 221AD302 and 221AD205 | No dispute reported | 06/30/2026 | 1236947322 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $25,631.10 | 01/28/2025 | Non-covered Recipient Entity CLINICAL SITE PARTNERS LLC | A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE | No dispute reported | 06/30/2026 | 1192127251 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $5,470.70 | 01/27/2025 | Non-covered Recipient Entity Alzheimers Memory Center Flourish Research | A Randomized, Double-blind, Placebo-controlled, Global Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986446, an Anti-MTBR Tau Monoclonal Antibody, in Participants with Early Alzheimers Disease (TargetTau-1) | No dispute reported | 06/30/2026 | 1235999065 |
| Principal investigator 1 | Eli Lilly and Company | $4,055.55 | 01/27/2025 | Non-covered Recipient Entity ALZHEIMER'S MEMORY CENTER | ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | No dispute reported | 06/30/2026 | 1187874437 |
| Principal investigator 1 | Eli Lilly and Company | $375.00 | 01/27/2025 | Non-covered Recipient Entity ALZHEIMERS MEMORY CENTER | ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | No dispute reported | 06/30/2026 | 1187876225 |
| Principal investigator 1 | Eli Lilly and Company | $793,691.00 | 01/22/2025 | Non-covered Recipient Entity FLOURISH RESEARCH ACQUISITION LLC | A RANDOMIZED, DOUBLE-BLINDED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MEVIDALEN IN PATIENTS WITH ALZHEIMER'S DISEASE | No dispute reported | 06/30/2026 | 1187881190 |
| Principal investigator 1 | Eli Lilly and Company | $28,407.00 | 01/21/2025 | Non-covered Recipient Entity ALZHEIMER'S MEMORY CENTER | ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | No dispute reported | 06/30/2026 | 1187876227 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $61,871.40 | 01/03/2025 | Non-covered Recipient Entity Alzheimers Memory Center Flourish Research | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Psychosis Associated with Alzheimers Disease (ADEPT-4) | No dispute reported | 06/30/2026 | 1235999055 |
| Principal investigator 1 | Eisai Inc. | $9,255.00 | 01/01/2025 | Non-covered Recipient Entity AMC Research LLC | A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) | No dispute reported | 06/30/2026 | 1244557459 |
| Principal investigator 1 | Eisai Inc. | $18,965.00 | 01/01/2025 | Non-covered Recipient Entity AMC Research LLC | A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) | No dispute reported | 06/30/2026 | 1244557463 |